Global burden, risk factors, and temporal trends of ureteral cancer: a comprehensive analysis of cancer registries.
Incidence
Risk factors
Temporal trends
Ureteral cancer
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
24 Jun 2024
24 Jun 2024
Historique:
received:
27
09
2023
accepted:
13
06
2024
medline:
25
6
2024
pubmed:
25
6
2024
entrez:
24
6
2024
Statut:
epublish
Résumé
Ureteral cancer is a rare cancer. This study aimed to provide an up-to-date and comprehensive analysis on the global trends of ureteral cancer incidence and its association with lifestyle and metabolic risk factors. The incidence of ureteral cancer was estimated from the Cancer Incidence in Five Continents Plus and Global Cancer Observatory databases. We analyzed the (1) global incidence of ureteral cancer by region, country, sex, and age group by age-standardized rates (ASR); (2) associated risk factors on a population level by univariable linear regression with logarithm transformation; and (3) incidence trend of ureteral cancer by sex and age group in different countries by Average Annual Percentage Change (AAPC). The global age-standardized rate of ureteral cancer incidence in 2022 was 22.3 per 10,000,000 people. Regions with higher human development index (HDI), such as Europe, Northern America, and East Asia, were found to have a higher incidence of ureteral cancer. Higher HDI and gross domestic product (GDP) and a higher prevalence of smoking, alcohol drinking, physical inactivity, unhealthy dietary, obesity, hypertension, diabetes, and lipid disorder were associated with higher incidence of ureteral cancer. An overall increasing trend of ureteral cancer incidence was observed for the past decade, especially among the female population. Although ureteral cancer was relatively rare, the number of cases reported was rising over the world. The rising trends among females were more evident compared with the other subgroups, especially in European countries. Further studies could be conducted to examine the reasons behind these epidemiological changes and confirm the relationship with the risk factors identified.
Sections du résumé
BACKGROUND
BACKGROUND
Ureteral cancer is a rare cancer. This study aimed to provide an up-to-date and comprehensive analysis on the global trends of ureteral cancer incidence and its association with lifestyle and metabolic risk factors.
METHODS
METHODS
The incidence of ureteral cancer was estimated from the Cancer Incidence in Five Continents Plus and Global Cancer Observatory databases. We analyzed the (1) global incidence of ureteral cancer by region, country, sex, and age group by age-standardized rates (ASR); (2) associated risk factors on a population level by univariable linear regression with logarithm transformation; and (3) incidence trend of ureteral cancer by sex and age group in different countries by Average Annual Percentage Change (AAPC).
RESULTS
RESULTS
The global age-standardized rate of ureteral cancer incidence in 2022 was 22.3 per 10,000,000 people. Regions with higher human development index (HDI), such as Europe, Northern America, and East Asia, were found to have a higher incidence of ureteral cancer. Higher HDI and gross domestic product (GDP) and a higher prevalence of smoking, alcohol drinking, physical inactivity, unhealthy dietary, obesity, hypertension, diabetes, and lipid disorder were associated with higher incidence of ureteral cancer. An overall increasing trend of ureteral cancer incidence was observed for the past decade, especially among the female population.
CONCLUSIONS
CONCLUSIONS
Although ureteral cancer was relatively rare, the number of cases reported was rising over the world. The rising trends among females were more evident compared with the other subgroups, especially in European countries. Further studies could be conducted to examine the reasons behind these epidemiological changes and confirm the relationship with the risk factors identified.
Identifiants
pubmed: 38915094
doi: 10.1186/s12916-024-03485-x
pii: 10.1186/s12916-024-03485-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
264Informations de copyright
© 2024. The Author(s).
Références
Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 2011;107(7):1059–64.
pubmed: 20825397
doi: 10.1111/j.1464-410X.2010.09675.x
Geller SA, de Campos FPF. Ureteric carcinoma. Autops Case Rep. 2014;4(1):63–4.
pubmed: 28652995
pmcid: 5470567
doi: 10.4322/acr.2014.010
Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730–4.
pubmed: 28543959
doi: 10.1111/iju.13376
McLaughlin JK, Silverman DT, Hsing AW, et al. Cigarette smoking and cancers of the renal pelvis and ureter. Can Res. 1992;52(2):254–7.
Holmäng S, Holmberg E, Johansson SL. A population-based study of tumours of the renal pelvis and ureter: incidence, aetiology and histopathological findings. Scand J Urol. 2013;47(6):491–6.
pubmed: 23634644
doi: 10.3109/21681805.2013.795188
Wihlborg A, Johansen C. Incidences of kidney, pelvis, ureter, and bladder cancer in a nationwide, population-based cancer registry, Denmark, 1944–2003. Urology. 2010;75(5):1222–7.
pubmed: 19674774
doi: 10.1016/j.urology.2009.05.013
Cheon J, Kim C-S, Lee ES, et al. Survey of incidence of urological cancer in South Korea: a 15-year summary. Int J Urol. 2002;9(8):445–54.
pubmed: 12225342
doi: 10.1046/j.1442-2042.2002.00500.x
Ferlay J, Ervik M, Lam F, et al. In: Global Cancer Observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020. Available from: https://gco.iarc.fr/today . Accessed 15 Dec 2021.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Cancer Incidence in Five Continents plus: IARC CancerBase No. 9. Lyon, France: International Agency for Research on Cancer; 2020. http://ci5.iarc.fr/CI5plus/Default.aspx . Accessed: Dec 2022.
Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2019 (GBD 2019) results. Available at http://ghdx.healthdata.org/gbd-results-tool . Accessed Dec 2022.
United Nations. Human development classification, 2018 statistical update; 2018 http://hdr.undp.org/sites/default/files/2018_human_development_statistical_update.pdf . Accesses Dec 2022.
The World Bank. GDP per capita (current US$). 2020. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD . Accessed on 31 Jan 2022.
US National Cancer Institute. Number of joinpoints. 2023. https://surveillance.cancer.gov/help/joinpoint/setting-parameters/method-and-parameters-tab/number-of-joinpoints . Accessed 20 Mar 2024.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.
pubmed: 10649300
doi: 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z
Ugai T, Sasamoto N, Lee H-Y, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol. 2022;19(10):656–73.
pubmed: 36068272
pmcid: 9509459
doi: 10.1038/s41571-022-00672-8
Chen C-H, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci. 2012;109(21):8241–6.
pubmed: 22493262
pmcid: 3361449
doi: 10.1073/pnas.1119920109
Reitsma MB, Kendrick PJ, Ababneh E, et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. The Lancet. 2021;397(10292):2337–60.
doi: 10.1016/S0140-6736(21)01169-7
Fernández MI, Shariat SF, Margulis V, et al. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology. 2009;73(1):142–6.
pubmed: 18845322
doi: 10.1016/j.urology.2008.07.042
Shinka T, Sawada Y, Morimoto S, Fujinaga T, Nakamura J, Ohkawa T. Clinical study on urothelial tumors of dye workers in Wakayama City. J Urol. 1991;146(6):1504–7.
pubmed: 1942328
doi: 10.1016/S0022-5347(17)38151-X
Jbnsen O, Knudsen J, McLaughlin J, Sørensrn B. The Copenhagen case-control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. Int J Cancer. 1988;41(4):557–61.
doi: 10.1002/ijc.2910410414
Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dia Transplant. 1999;14(12):2892–7.
doi: 10.1093/ndt/14.12.2892
Riedel K, Scherer G, Engl J, Hagedorn H-W, Tricker AR. Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol. 2006;30(3):187–95.
pubmed: 16803653
doi: 10.1093/jat/30.3.187
Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003;3(10):733–44.
pubmed: 14570033
doi: 10.1038/nrc1190
Talaska G. Aromatic amines and human urinary bladder cancer: exposure sources and epidemiology. J Environ Sci Health C. 2003;21(1):29–43.
doi: 10.1081/GNC-120021372
Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol. 2022;19(5):280–94.
pubmed: 35361927
doi: 10.1038/s41585-022-00578-1
Zaitsu M, Kawachi I, Takeuchi T, Kobayashi Y. Alcohol consumption and risk of upper-tract urothelial cancer. Cancer Epidemiol. 2017;48:36–40.
pubmed: 28364670
doi: 10.1016/j.canep.2017.03.002
Tsukamoto S, Kanegae T, Uchigasaki S, et al. Changes in free and bound alcohol metabolites in the urine during ethanol oxidation. Arukoru Kenkyu to Yakubutsu Izon. 1993;28(6):441–52.
pubmed: 8129672
Malorny G, Rietbrock N, Schneider M. Die Oxydation des Formaldehyds zu Ameisensäure im Blut, ein Beitrag zum Stoffwechsel des Formaldehyds. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1965;250(4):419–36.
pubmed: 14334368
doi: 10.1007/BF00246893
Yoshida A, Hsu LC, Yasunami M. Genetics of human alcohol-metabolizing enzymes. Prog Nucleic Acid Res Mol Biol. 1991;40:255–87.
pubmed: 2031085
doi: 10.1016/S0079-6603(08)60844-2
Goedde HW, Agarwal DP, Fritze G, et al. Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet. 1992;88(3):344–6.
pubmed: 1733836
doi: 10.1007/BF00197271
Colin P, Koenig P, Ouzzane A, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 2009;104(10):1436–40.
pubmed: 19689473
doi: 10.1111/j.1464-410X.2009.08838.x
Lord GM, Cook T, Arit VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. The Lancet. 2001;358(9292):1515–6.
doi: 10.1016/S0140-6736(01)06576-X
Liaw KL, Linet MS, McLaughlin JK, et al. Possible relation between hypertension and cancers of the renal pelvis and ureter. Int J Cancer. 1997;70(3):265–8.
pubmed: 9033625
doi: 10.1002/(SICI)1097-0215(19970127)70:3<265::AID-IJC3>3.0.CO;2-V
Mahdavifar N, Ghoncheh M, Pakzad R, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of bladder cancer and their relationship with the development index in the world. Asian Pac J Cancer Prev. 2016;17(1):381–6.
pubmed: 26838243
doi: 10.7314/APJCP.2016.17.1.381
Teoh JYC, Huang J, Ko WYK, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol. 2020;78(6):893–906.
pubmed: 32972792
doi: 10.1016/j.eururo.2020.09.006
Rezaei F, Tabatabaee HR, Rahmanian V, Mirahmadizadeh A, Hassanipour S. The correlation between bladder cancer and obesity, overweight, physical inactivity, and tobacco use: an ecological study in Asian countries. Ann Glob Health. 2019;85(1):102.
pubmed: 31298827
pmcid: 6634367
doi: 10.5334/aogh.2545
Lin Y, Wang Y, Wu Q, et al. Association between obesity and bladder cancer recurrence: a meta-analysis. Clin Chim Acta. 2018;480:41–6.
pubmed: 29408169
doi: 10.1016/j.cca.2018.01.039
Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819–23.
pubmed: 17021919
doi: 10.1007/s00125-006-0468-0
Shih HJ, Lin KH, Wen YC, Fan YC, Tsai PS, Huang CJ. Increased risk of bladder cancer in young adult men with hyperlipidemia: a population-based cohort study. Medicine (Baltimore). 2021;100(48):e28125.
pubmed: 35049242
doi: 10.1097/MD.0000000000028125
Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.
pubmed: 24454289
pmcid: 3887317
doi: 10.3389/fphar.2013.00177
Bandaranayake WM. Quality control, screening, toxicity, and regulation of herbal drugs. In: Modern phytomedicine: turning medicinal plants into drugs. 2006. p. 25–57.
doi: 10.1002/9783527609987.ch2
Nissen N. Practitioners of Western herbal medicine and their practice in the UK: beginning to sketch the profession. Complement Ther Clin Pract. 2010;16(4):181–6.
pubmed: 20920799
doi: 10.1016/j.ctcp.2010.06.001
Calapai G. European legislation on herbal medicines. Drug Saf. 2008;31(5):428–31.
pubmed: 18422385
doi: 10.2165/00002018-200831050-00009
Chau W, Ross R, Li JY, Yong TY, Klebe S, Barbara JA. Nephropathy associated with use of a Chinese herbal product containing aristolochic acid. Med J Aust. 2011;194(7):367–8.
pubmed: 21470089
doi: 10.5694/j.1326-5377.2011.tb03011.x
Michl J, Jennings HM, Kite GC, Ingrouille MJ, Simmonds MSJ, Heinrich M. Is aristolochic acid nephropathy a widespread problem in developing countries?: a case study of Aristolochia indica L. in Bangladesh using an ethnobotanical–phytochemical approach. J Ethnopharmacol. 2013;149(1):235–44.
pubmed: 23806867
doi: 10.1016/j.jep.2013.06.028
Gouws C, Hamman JH. What are the dangers of drug interactions with herbal medicines? Expert Opin Drug Metab Toxicol. 2020;16(3):165–7.
pubmed: 32079422
doi: 10.1080/17425255.2020.1733969